KeChow Pharma announces that its drug Tunlametinib (HL-085) has been approved by the NMPA, becoming the first targeted therapy approved for the treatment of NRAS-mutant advanced melanoma patients who have been previously treated with PD-1/PD-L1 therapy.

Takeda Pharmaceutical's approval of colchicine in January 1995 marked a significant milestone in the world of medicine.

Shaperon has initiated enrollment of its inaugural participant in the second-stage American clinical study for its eczema treatment, branded as Nugel.

This article summarizes GPCR targets and pipelines highlighted by AstraZeneca, Pfizer, and Eli Lilly at JP Morgan Healthcare Conference 2024.

Promising phase III results for RUBY suggest expanded use of Jemperli (dostarlimab-gxly) paired with other treatments in cases of initial severe or returning uterine cancer.

Benzoyl peroxide, a small molecule drug with potent antibacterial properties, was originally sanctioned in January 1968 by Maruho Pharmaceutical for treating acne.

AstraZeneca plans to purchase Amolyt Pharma, thereby broadening its advanced portfolio in uncommon disorders.

This article will introduce the GPCR targets and pipelines that received attention at the JP Morgan Healthcare Conference 2024.

Lirum BioMed Reveals Encouraging Results for Its Innovative Treatment LX-101, Showing Strong Early-Phase Effectiveness in Tackling IGF-Linked Tumors, Scheduled for Discussion at the 2024 ESMO Congress on Sarcoma and Uncommon Cancers.

Levetiracetam, a diminutive molecular entity, has been engineered to hone in on the synaptic vesicle protein 2A (SV2A) as a modulation target.

Nuvectis Pharma Releases Promising Initial Results from Early-Stage NXP800 Study in Platinum-Resilient Ovarian Cancer with ARID1a Alterations.

On March 11th, Boehringer Ingelheim partnered with Sosei Group in an exclusive deal to create and market a novel schizophrenia drug, a GPR52 agonist.